Novartis to invest $100m in new malaria treatments

05:20 EDT 17 Apr 2018 | Pharmafile

Novartis has revealed it is to invest $100 million into the research and development of new treatments for malaria over the next five years, another crucial step in the World Health Organization’s goal to reduce child mortality related to the disease by 90% by 2030.

The investment will cover the development of Novartis’ malaria pipeline through to 2023, including the completion of a global clinical trial programme for its antimalarial candidates KAF156 and KAE609, both of which are currently at Phase 2.

read more

Original Article: Novartis to invest $100m in new malaria treatments


More From BioPortfolio on "Novartis to invest $100m in new malaria treatments"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Tropical Medicine
Tropical Medicine is the study of diseases more commonly found in tropical regions than elsewhere. Examples of these diseases are malaria, yellow fever, Chagas disease, Dengue, Helminths, African trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic filaria...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...